← back to search

Gioacchino Natoli

European Institute of Oncology · IT
Area of research
Immunology · Molecular Biology
Research interest
Research interests include Epigenetics and DNA Methylation, Immune Response and Inflammation, NF-κB Signaling Pathways, and Immune cells in cancer.
h-index
77
citations
34,261
works
243
NIH funding
primary concept
Biology
email

Recent publications

FCRL3 is an immunoregulatory receptor that restrains the activation of human memory T lymphocytes.
2026cited by 1position: contributordoi
Control of myeloid lineage fidelity and response to stimuli by ISWI-enforced nucleosome phasing.
2025cited by 1position: contributordoi
Leveraging the tug-of-war with genomic retroelements to enhance immunotherapy of pancreatic cancer.
2025cited by 0position: contributordoi
A framework to mine laser microdissection-based omics data and uncover regulators of pancreatic cancer heterogeneity.
2025cited by 0position: contributordoi
Cancer Evolution: A Multifaceted Affair.
2024cited by 54position: contributordoi
Mapping functional to morphological variation reveals the basis of regional extracellular matrix subversion and nerve invasion in pancreatic cancer.
2024cited by 50position: contributordoi
The landscape of cancer-rewired GPCR signaling axes
Cell Genomics 2024cited by 22position: middledoi
The landscape of cancer-rewired GPCR signaling axes.
2024cited by 20position: contributordoi
Activation of endogenous retroviruses and induction of viral mimicry by MEK1/2 inhibition in pancreatic cancer.
2024cited by 20position: contributordoi
Acetyl-CoA production by Mediator-bound 2-ketoacid dehydrogenases boosts de novo histone acetylation and is regulated by nitric oxide.
2024cited by 16position: contributordoi
An integrative epigenome-based strategy for unbiased functional profiling of clinical kinase inhibitors.
2024cited by 2position: contributordoi
High-sensitivity analysis of clonal hematopoiesis reveals increased clonal complexity of potential-driver mutations in severe COVID-19 patients.
2024cited by 1position: contributordoi
Learning and actioning general principles of cancer cell drug sensitivity
2024cited by 1position: contributordoi
Cancer Evolution: A Multifaceted Affair
Cancer Discovery 2023cited by 70position: middledoi
Restrictor synergizes with Symplekin and PNUTS to terminate extragenic transcription.
2023cited by 20position: contributordoi
Interferon regulatory factor 1 (IRF1) controls the metabolic programmes of low-grade pancreatic cancer cells.
2023cited by 12position: contributordoi
ADP-ribosyltransferases, an update on function and nomenclature.
2022cited by 266position: contributordoi
Current challenges in understanding the role of enhancers in disease.
2022cited by 73position: contributordoi
Longitudinal multi-omics analysis identifies early blood-based predictors of anti-TNF therapy response in inflammatory bowel disease.
2022cited by 50position: contributordoi
DNA methyltransferase 3A controls intestinal epithelial barrier function and regeneration in the colon.
2022cited by 34position: contributordoi
H3K9 trimethylation in active chromatin restricts the usage of functional CTCF sites in SINE B2 repeats.
2022cited by 25position: contributordoi
Lower probability and shorter duration of infections after COVID-19 vaccine correlate with anti-SARS-CoV-2 circulating IgGs.
2022cited by 19position: contributordoi
RFX transcription factors control a miR-150/PDAP1 axis that restrains the proliferation of human T cells.
2022cited by 9position: contributordoi
Coexisting morpho-biotypes unveil the regulatory bases of phenotypic plasticity in pancreatic ductal adenocarcinoma
2022cited by 2position: contributordoi
Clonal hematopoiesis, inflammation, and cardiovascular disorders: a mitochondrial connection.
2022cited by 1position: contributordoi
ADP‐ribosyltransferases, an update on function and nomenclature
FEBS Journal 2021cited by 322position: middledoi
Epithelial memory of inflammation limits tissue damage while promoting pancreatic tumorigenesis.
2021cited by 200position: contributordoi
A first exon termination checkpoint preferentially suppresses extragenic transcription.
2021cited by 48position: contributordoi
Integration of transcriptional and metabolic control in macrophage activation.
2021cited by 26position: contributordoi
Tumor cell heterogeneity and its transcriptional bases in pancreatic cancer: a tale of two cell types and their many variants.
2021cited by 23position: contributordoi

Grants

No grants ingested yet.

Frequent collaborators

· 16 papers (2019–2026)Pier Giuseppe Pelicci · Molecular Oncology (United States)8 papers (2019–2022) · 6 papers (2019–2026) · 5 papers (2021–2025)Alessandro Zerbi · Humanitas University5 papers (2019–2024)Sara Gandini · Institute for Experimental Endocrinology and Oncology4 papers (2020–2022)Iros Barozzi · University Hospital of Zurich4 papers (2019–2025)Nico Mitro · Ospedale San Giuseppe3 papers (2023–2024) · 3 papers (2023–2025)Sara Raimondi · University of Pavia3 papers (2020–2022)Iros Barozzi · University Hospital of Zurich2 papers (2012–2012)Mara Cetty Spinella · Università della Svizzera italiana2 papers (2024–2026)Federica Facciotti · Istituti di Ricovero e Cura a Carattere Scientifico2 papers (2020–2020)Silvia Monticelli · Università della Svizzera italiana2 papers (2024–2026) · 2 papers (2024–2024)Serena Ghisletti · University of Milan2 papers (2021–2024)Federico Forneris · Istituti di Ricovero e Cura a Carattere Scientifico2 papers (2020–2020)Sebastiano Pasqualato · Human Technopole2 papers (2020–2022)Philip Rosenstiel · Vall d'Hebron Hospital Universitari2 papers (2022–2022) · 2 papers (2019–2021)